Glucocorticoid replacement therapy and vertebral fractures in hypopituitary adult males with GH deficiency

European Journal of Endocrinology

Volumn 163, Issue 1, 2010, Pages 15-20

  Mazziotti, G ^a   Porcelli, T ^a   Bianchi, A ^b   Cimino, V ^b   Patelli, I ^a   Mejia, C ^a   Fusco, A ^b   Giampietro, A ^b   De Marinis, L ^b   Giustina, A ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CORTISONE; GLUCOCORTICOID; GROWTH HORMONE; TESTOSTERONE ENANTATE; TESTOSTERONE PROPIONATE;

ADULT; AGED; ARTICLE; BONE DENSITY; CONTROLLED STUDY; CORTICOSTEROID INDUCED OSTEOPOROSIS; CROSS-SECTIONAL STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; GROWTH HORMONE DEFICIENCY; HUMAN; HYDROCORTISONE URINE LEVEL; HYPOGONADISM; HYPOPITUITARISM; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; TREATMENT OUTCOME; VERTEBRA FRACTURE;

ADULT; AGED; AGED, 80 AND OVER; GLUCOCORTICOIDS; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; HYDROCORTISONE; LOGISTIC MODELS; MALE; MIDDLE AGED; SPINAL FRACTURES; TESTOSTERONE; YOUNG ADULT;

EID: 77954120803     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-10-0125     Document Type: Article

References (40)

1. Mazziotti G, Angeli A, Bilezikian JP, Canalis E & Giustina A. Glucocorticoid-induced osteoporosis: an update. Trends in Endocrinology and Metabolism 2006 17 144-149.
2. Canalis E & Giustina A. Glucocorticoid-induced osteoporosis: summary of a workshop. Journal of Clinical Endocrinology and Metabolism 2001 86 5681-5685.
3. Wichers M, Springer W, Bidlingmaier F & Klingmuller D. The influence of hydrocortisone substitution on the quality of life and parameters of bone metabolism in patients with secondary hypocortisolism. Clinical Endocrinology 1999 50 759-765.
4. Zelissen PM, Croughs RJ, van Rijk PP & Raymakers JA. Effect of glucocorticoid replacement therapy on bone mineral density in patients with Addison disease. Annals of Internal Medicine 1994 120 207-210.
5. Jódar E, Valdepeñas MP, Martinez G, Jara A & Hawkins F. Long-term follow-up of bone mineral density in Addison's disease. Clinical Endocrinology 2003 58 617-620.
6. Braatvedt GD, Joyce M, Evans M, Clearwater J & Reid IR. Bone mineral density in patients with treated Addison's disease. Osteoporosis International 1999 10 435-440. (Pubitemid 30029008)
7. Vestergaard P, Rejnmark L & Mosekilde L. Fracture risk associated with different types of oral corticosteroids and effect of termination of corticosteroids on the risk of fractures. Calcified Tissue International 2008 82 249-257.
8. Giustina A, Mazziotti G & Canalis E. Growth hormone, insulin-like growth factors, and the skeleton. Endocrine Reviews 2008 29 535-559.
9. Canalis E, Giustina A & Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. New England Journal of Medicine 2007 357 905-916.
10. Digirolamo DJ, Mukherjee A, Fulzele K, Gan Y, Cao X, Frank SJ & Clemens TL. Mode of growth hormone action in osteoblasts. Journal of Biological Chemistry 2007 282 31666-31674.
11. Doga M, Bonadonna S, Gola M, Mazziotti G, Nuzzo M & Giustina A. GH deficiency in the adult and bone. Journal of Endocrinological Investigation 2005 28 (Suppl 8) 18-23.
12. Rosen T, Wilhelmsen L, Landin-Wilhelmsen K, Lappas G & Bengtsson BA. Increased fracture frequency in adult patients with hypopituitarism and GH deficiency. European Journal of Endocrinology 1997 137 240-245. (Pubitemid 27405107)
13. Wuster C, Abs R, Bengtsson BA, Bennmarker H, Feldt-Rasmussen U, Hernberg-Stahl E, Monson JP, Westberg B, Wilton P & KIMS Study Group and the KIMS International Board Pharmacia & Upjohn International Metabolic Database. The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. Journal of Bone and Mineral Research 2001 16 398-405.
14. Bouillon R, Koledova E, Bezlepkina O, Nijs J, Shavrikhova E, Nagaeva E, Chikulaeva O, Peterkova V, Dedov I, Bakulin A, Oganov V & Attanasio AF. Bone status and fracture prevalence in Russian adults with childhood-onset growth hormone deficiency. Journal of Clinical Endocrinology and Metabolism 2004 89 4993-4998. (Pubitemid 39391439)
15. Mazziotti G, Bianchi A, Bonadonna S, NuzzoM, Cimino V, Fusco A, De Marinis L & Giustina A. Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy. Journal of Bone and Mineral Research 2006 21 520-528.
16. Vestergaard P, Jørgensen JO, Hagen C, Hoeck HC, Laurberg P, Rejnmark L, Brixen K, Weeke J, Andersen M, Conceicao FL, Nielsen TL & Mosekilde L. Fracture risk is increased in patients with GH deficiency or untreated prolactinomas - a case-control study. Clinical Endocrinology 2002 56 159-167. (Pubitemid 34234798)
17. Danilowicz K, Bruno OD, Manavela M, Gomez RM & Barkan A. Correction of cortisol overreplacement ameliorates morbidities in patients with hypopituitarism: a pilot study. Pituitary 2008 11 279-285.
18. Filipsson H, Monson JP, Koltowska-Häggström M, Mattsson A & Johannsson G. The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. Journal of Clinical Endocrinology and Metabolism 2006 91 3954-3961. (Pubitemid 44536870)
19. al-Shoumer KA, Beshyah SA, Niththyananthan R & Johnston DG. Effect of glucocorticoid replacement therapy on glucose tolerance and intermediary metabolites in hypopituitary adults. Clinical Endocrinology 1995 42 85-90.
20. Filipsson H & Johannsson G. GH replacement in adults: interactions with other pituitary hormone deficiencies and replacement therapies. European Journal of Endocrinology 2009 161 (Suppl 1) S85-S95.
21. Kanis JA, Delmas P, Burckhardt P, Cooper C & Torgerson D. Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. Osteoporosis International 1997 7 390-406.
22. Debono M, Price JN & Ross RJ. Novel strategies for hydrocortisone replacement. Best Practice & Research. Clinical Endocrinology & Metabolism 2009 23 221-232.
23. Esteban NV, Loughlin T, Yergey AL, Zawadzki JK, Booth JD, Winterer JC & Loriaux DL. Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry. Journal of Clinical Endocrinology and Metabolism 1991 72 39-45. (Pubitemid 21921653)
24. Kraan GP, Dullaart RP, Pratt JJ, Wolthers BG, Drayer NM & De Bruin R. The daily cortisol production reinvestigated in healthy men. The serum and urinary cortisol production rates are not significantly different. Journal of Clinical Endocrinology and Metabolism 1998 83 1247-1252. (Pubitemid 28496402)
25. Trainer PJ, McHardy KC, Harvey RD & Reid IW. Urinary free cortisol in the assessment of hydrocortisone replacement therapy. Hormone and Metabolic Research 1993 25 117-120.
26. Majumdar SR, Kim N, Colman I, Chahal AM, Raymond G, Jen H, Siminoski KG, Hanley DA & Rowe BH. Incidental vertebral fractures discovered with chest radiography in the emergency department: prevalence, recognition, and osteoporosis management in a cohort of elderly patients. Archives of Internal Medicine 2005 165 905-909.
27. Mazziotti G, Bianchi A, Cimino V, Bonadonna S, Martini P, Fusco A, De Marinis L & Giustina A. Effect of gonadal status on bone mineral density and radiological spinal deformities in adult patients with growth hormone deficiency. Pituitary 2008 11 55-61. (Pubitemid 351168085)
28. Wake DJ, Rask E, Livingstone DE, Soderberg S, Olsson T & Walker BR. Local and systemic impact of transcriptional up-regulation of 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue in human obesity. Journal of Clinical Endocrinology and Metabolism 2003 88 3983-3988. (Pubitemid 37034555)
29. Canalis E, Mazziotti G, Giustina A & Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporosis International 2007 18 1319-1328.
30. Bonadonna S, Mazziotti G, Nuzzo M, Bianchi A, Fusco A, De Marinis L & Giustina A. Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women. Journal of Bone and Mineral Research 2005 20 1837-1844. (Pubitemid 41361885)
31. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes - a meta-analysis. Osteoporosis International 2007 18 427-444. (Pubitemid 46354916)
32. Mazziotti G, Bianchi A, Bonadonna S, Cimino V, Patelli I, Fusco A, Pontecorvi A, De Marinis L & Giustina A. Prevalence of vertebral fractures in men with acromegaly. Journal of Clinical Endocrinology and Metabolism 2008 93 4649-4655.
33. Giustina A, Bussi AR, Jacobello C & Wehrenberg WB. Effects of recombinant human growth hormone (GH) on bone and intermediary metabolism in patients receiving chronic glucocorticoid treatment with suppressed endogenous GH response to GH-releasing hormone. Journal of Clinical Endocrinology and Metabolism 1995 80 122-129.
34. Bechtold S, Ripperger P, Bonfig W, Dalla Pozza R, Häfner R & Schwarz H. Growth hormone changes bone geometry and body composition in patients with juvenile idiopathic arthritis requiring glucocorticoid treatment: a controlled study using peripheral quantitative computed tomography. Journal of Clinical Endocrinology and Metabolism 2005 90 3168-3173. (Pubitemid 41014270)
35. Swords FM, Carroll PV, Kisalu J, Wood PJ, Taylor NF & Monson JP. The effects of growth hormone deficiency and replacement on glucocorticoid exposure in hypopituitary patients on cortisone acetate and hydrocortisone replacement. Clinical Endocrinology 2003 59 613-620. (Pubitemid 37357623)
36. Giavoli C, Libe R, Corbetta S, Ferrante E, Lania A, Arosio M, Spada A & Beck-Peccoz P. Effect of recombinant human growth hormone (GH) replacement on the hypothalamic-pituitary-adrenal axis in adult GH-deficient patients. Journal of Clinical Endocrinology and Metabolism 2004 89 5397-5401. (Pubitemid 39518415)
37. van Staa TP, Leufkens HG, Abenhaim L, Zhang B & Cooper C. Use of oral corticosteroids and risk of fractures. Journal of Bone and Mineral Research 2000 15 993-1000. (Pubitemid 30350061)
38. Reeve J, Lunt M, Felsenberg D, Silman AJ, Scheidt-Nave C, Poor G, Gennari C,Weber K, Lorenc R, Masaryk P, Cannata JB, Dequeker J, Reid DM, Pols HA, Benevolenskaya LI, Stepan JJ, Miazgowski T, Bhalla A, Bruges Armas J, Eastell R, Lopes-Vaz A, Lyritis G, Jajic I, Woolf AD, Banzer D, Reisinger W, Todd CJ, Felsch B, Havelka S, Hoszowski K, Janott J, Johnell O, Raspe HH, Yershova OB, Kanis JA, Armbrecht G, Finn JD, Gowin W, O'Neill TW & European Prospective Osteoporosis Study Group. Determinants of the size of incident vertebral deformities in European men and women in the sixth to ninth decades of age: the European prospective osteoporosis study. Journal of Bone and Mineral Research 2003 18 1664-1673.
39. Silverman SL, Minshall ME, Shen W, Harper KD, Xie S & Health- Related Quality of Life Subgroup of the Multiple Outcomes of Raloxifene Evaluation Study. The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from the multiple outcomes of raloxifene evaluation study. Arthritis and Rheumatism 2001 44 2611-2619.
40. O'Neill TW, Cockerill W, Matthis C, Raspe HH, Lunt M, Cooper C, Banzer D, Cannata JB, Naves M, Felsch B, Felsenberg D, Janott J, Johnell O, Kanis JA, Kragl G, Lopes Vaz A, Lyritis G, Masaryk P, Poor G, Reid DM, Reisinger W, Scheidt-Nave C, Stepan JJ, Todd CJ, Woolf AD, Reeve J & Silman AJ. Back pain, disability, and radiographic vertebral fracture in European women: a prospective study. Osteoporosis International 2004 15 760-765.